Dr. Mateos on Elderly Patients With Newly Diagnosed MM

María-Victoria Mateos
Published Online: Monday, Dec 16, 2013

María-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology (ASH) Meeting.

In the GEM2010MAS65 trial, researchers conducted a comparison of sequential and alternating administration of bortezomib, melphalan, and prednisone and lenalidomide plus dexamethasone in elderly patients with newly diagnosed multiple myeloma.

The combination of melphalan, bortezomib, lenalidomide, and steroids in this patient population in a sequential or alternating scheme is feasible, Mateos says. In terms of complete remission, the alternating scheme showed superior efficacy, though a longer follow-up is needed.

María-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology (ASH) Meeting.

In the GEM2010MAS65 trial, researchers conducted a comparison of sequential and alternating administration of bortezomib, melphalan, and prednisone and lenalidomide plus dexamethasone in elderly patients with newly diagnosed multiple myeloma.

The combination of melphalan, bortezomib, lenalidomide, and steroids in this patient population in a sequential or alternating scheme is feasible, Mateos says. In terms of complete remission, the alternating scheme showed superior efficacy, though a longer follow-up is needed.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Newer Options on the Horizon for Non-Small Cell Lung CancerJul 20, 20161.0
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 20, 20162.5